Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | 0.00% | 0.00% | 0.00% |
01-26 | Optimind Pharma Reaches Agreement On Debenture Conversion | MT |
01-10 | Optimind Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 | CI |
Sales 2022 | 99.69K 72.86K | Sales 2023 | 170K 124K | Capitalization | 3.91M 2.86M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -3M -2.19M | EV / Sales 2022 * | - |
Net cash position 2022 | 1.22M 891K | Net Debt 2023 | 61.19K 44.72K | EV / Sales 2023 | 23.4 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-1.07
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.31% |
6 months | -80.00% |
Date | Price | Change | Volume |
---|
Delayed Quote Canadian Securities Exchange, May 02, 2024 at 03:46 pm
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 358K | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- OMND Stock